Core Insights - The 17th China Bioindustry Conference showcased cutting-edge technologies in the biofield, emphasizing the theme "Biotechnology Empowers the Future, Biomanufacturing Reshapes the World" [1] - The conference serves as a significant booster for China's bioindustry development, facilitating deep connections between industry, academia, and research to accelerate technology transfer and resource integration [1] Company Highlights - Shanghai United Imaging Healthcare Co., Ltd. presented the world's first 5.0T whole-body MRI system, uMR Jupiter 5T, which offers high-definition imaging for precise diagnosis and seamless integration of research and clinical applications [1] - Wuhan Heyuan Biotechnology Co., Ltd. introduced the first recombinant human albumin injection derived from rice, which alleviates reliance on imported products and is set to achieve an annual production capacity of 12 million bottles by 2026 [2] - BGI Life Sciences Research Institute announced the Stereo-seq V2 technology, a groundbreaking spatial transcriptomics method compatible with FFPE samples, enabling high-resolution analysis of host and microbial interactions in clinical settings [3] Industry Trends - The bioindustry is transitioning from "quantitative accumulation" to "qualitative leap," focusing on core technology breakthroughs, product quality upgrades, and enhancing supply chain resilience [7] - Innovations in synthetic biology and gene editing are driving rapid growth in biomanufacturing, with artificial intelligence playing a crucial role in life science advancements [7] - Future developments in the bioindustry are expected to concentrate on cutting-edge fields such as synthetic biology and brain science to build core competitiveness [7]

Core Insights - The 17th China Bioindustry Conference showcased cutting-edge technologies in the biological field, emphasizing the theme "Biotechnology Empowers the Future, Biomanufacturing Reshapes the World" [1] - The conference serves as a significant booster for the development of China's bioindustry, facilitating deep integration of industry, academia, and research to accelerate technology transfer and resource integration [1] Company Highlights - Shanghai United Imaging Healthcare Co., Ltd. presented the world's first 5.0T whole-body MRI system, uMRJupiter5T, which offers high-definition imaging for precise diagnosis [1] - Wuhan Heyuan Biotechnology Co., Ltd. introduced the first recombinant human albumin injection derived from rice, which alleviates reliance on imported products and is set to achieve an annual production capacity of 12 million bottles by 2026 [2] - BGI Life Sciences Research Institute announced the global first Stereo-seqV2 technology for spatial transcriptomics, which addresses the challenges of analyzing FFPE samples and has significant implications for precision medicine [3] Technological Innovations - The conference highlighted advancements in brain-machine interface technologies, including a near-infrared brain function imaging system that is the first in China to receive NMPA certification, enabling non-invasive detection of brain activity [4][5] - The high-throughput implantable brain-machine interface system showcased by Wuhan Zhonghua Brain-Machine Fusion Technology Development Co., Ltd. features 65,000 channels for bidirectional functionality, marking a significant leap in system capabilities [5] - The NeuroTuneA1 system developed by Tongji Hospital utilizes focused ultrasound for non-invasive brain-machine treatment, with successful concept validation and animal model testing [6] Industry Trends - China's bioindustry is transitioning from "quantitative accumulation" to "qualitative leap," focusing on core technology breakthroughs, product quality upgrades, and enhancing industry chain resilience [7] - Innovations in synthetic biology and gene editing are driving rapid growth in biomanufacturing, with artificial intelligence playing a crucial role in life science innovation [7] - Future developments in the bioindustry are expected to concentrate on cutting-edge fields such as synthetic biology and brain science to build core competitive advantages [7]

合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 2025年2月10日，中国植入式脑机接口领域的创新先锋—— 阶梯医疗宣布完成 3.5亿元 人民币B轮融资 ， 这是中国植入式脑机接口行业历史上最大的一笔融资 。 本轮融资由 启明创投 、 奥博资本 、 礼来亚洲基金 等知名投资机构共同领投，天使轮投资机构 源来资本 持续跟投， 启峰资本 担任财务顾问。 本轮资金将用于加速产品临床试验、新一代技术研发以及医疗级MEMS生产基地建设，为脑机接口技术的商 业化落地提供强力支撑。 # 公司介绍 市场表现 阶梯医疗成立于2021年8月，总部位于上海，专注于微创植入式脑机接口技术的研发与应用。公司成功研制出 中国首款符合医疗器械标准的高通量植入式脑机接口系统，是中国首个完成注册性型式检验的侵入式脑机接口 产品。凭借该项目，阶梯医疗入选工信部2023年未来产业创新任务"揭榜挂帅"项目名单，是上海市唯一获评的 植入式脑机接口企业，并获得上海市2024年度"科技创新行动计划"脑机接口项目支持。 产品与技术介绍 技术特点 阶 ...

国内首个完成注册性型式检验的植入式脑机接口企业。 成立于2021年8月 的 阶梯医疗专注于微创植入式脑机接口技术的研发与应用。与Neuralink一样， 阶梯医疗选择了技术难度与应用天花板最高的侵入式脑机接口技术路径，并成功研制出中国首款符合 医疗器械标准的高通量植入式脑机接口系统，旨在帮助瘫痪患者完成复杂的脑控任务，是中国首个完 成注册性型式检验的侵入式脑机接口产品。 目前，阶梯医疗已与国内多家顶尖医院合作，开展了累积超过50例脑机接口相关研究者发起的临床 研究（IIT），取得了显著的临床效果，并建成全球规模最大的柔性电极人体单细胞数据集。阶梯医 疗计划于2025年启动国内首个侵入式脑机接口长期埋植前瞻性临床试验（FIM），2026年进一步推 进大规模临床试验，为产品注册上市铺平道路。 在神经电极技术方面，阶梯医疗实现了革命性突破：采用超柔性电极设计，尺寸仅为头发丝的 1/100（Neuralink的1/5），柔软程度优于Neuralink数百倍，使得脑组织很难"感受到"电极的"外 来侵入"，首次开发出未形成免疫瘢痕的神经电极界面，保证了长期稳定的神经活动记录。通过引入 半导体微纳加工工艺，公司解决了医疗级 ...